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Abstract
Background: Increase of the expression of γ-globin gene and high production of fetal hemoglobin (HbF) in
β-thalassemia patients is widely accepted as associated with a milder or even asymptomatic disease. The
search for HbF-associated polymorphisms (such as the XmnI, BCL11A and MYB polymorphisms) has recently
gained great attention, in order to stratify β-thalassemia patients with respect to expectancy of the first
transfusion, need for annual intake of blood, response to HbF inducers (the most studied of which is hydroxyurea).
Methods: Aγ-globin gene sequencing was performed on genomic DNA isolated from a total of 75 β-thalassemia
patients, including 31 β039/β039, 33 β039/β+IVSI-110, 9 β+IVSI-110/β+IVSI-110, one β0IVSI-1/β+IVSI-6 and one β039/
β+IVSI-6.
Results: The results show that the rs368698783 polymorphism is present in β-thalassemia patients in the
5’UTR sequence (+25) of the Aγ-globin gene, known to affect the LYAR (human homologue of mouse Ly-1
antibody reactive clone) binding site 5′-GGTTAT-3′. This Aγ(+25 G->A) polymorphism is associated with the
Gγ-globin-XmnI polymorphism and both are linked with the β039-globin gene, but not with the β+IVSI-110-
globin gene. In agreement with the expectation that this mutation alters the LYAR binding activity, we found
that the Aγ(+25 G->A) and Gγ-globin-XmnI polymorphisms are associated with high HbF in erythroid
precursor cells isolated from β039/β039 thalassemia patients.
Conclusions: As a potential explanation of our findings, we hypothesize that in β-thalassemia the Gγ-globin-
XmnI/Aγ-globin-(G->A) genotype is frequently under genetic linkage with β0-thalassemia mutations, but not
with the β+-thalassemia mutation here studied (i.e. β+IVSI-110) and that this genetic combination has been
selected within the population of β0-thalassemia patients, due to functional association with high HbF. Here
we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the Aγ-globin gene
associated in β039 thalassemia patients with high HbF in erythroid precursor cells.
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Background
The β-thalassemias are relevant hereditary hematological
diseases caused by nearly 300 mutations of the β-globin
gene, leading to low or absent production of adult β-
globin and excess of α-globin content in erythroid cells,
causing ineffective erythropoiesis and low or absent pro-
duction of adult hemoglobin (HbA) [1–5]. Increase of
the expression of γ-globin genes and high production of
fetal hemoglobin (HbF) in β-thalassemia patients is
widely accepted as associated with a milder or even
asymptomatic disease [6–8]. In several cases, high HbF
expressing β-thalassemia patients do not need transfu-
sion regimen and, consequently, chelation therapy [6–8].
This well recognized finding has prompted researchers to
develop efficient HbF inducers for treating β-thalassemia
patients expressing low levels of HbF [9–14]. On the other
hand, the search for HbF-associated polymorphisms (such
as the XmnI, BCL11A and MYB polymorphisms) [15–19]
has recently gained great attention, in order to stratify
β-thalassemia patients with respect to expectancy of
the first transfusion, need for annual intake of blood,
response to HbF inducers (the most studied of which
is hydroxyurea) [20–22].
In consideration of the fact that several HbF-related
polymorphisms probably act in synergy, the interest in
finding novel HbF-related genetic biomarkers has
remained high. This field of investigation, in addition to
a clear interest in diagnostics and prognostics, might
bring novel therapeutic options, in the case the polymor-
phism(s) is (are) associated with novel therapeutic
markers. This field of research has identified several dir-
ect or indirect transcriptional repressors of γ-globin
gene expression such as BCL11A, KLF1, MYB, Oct-1
[16–19].
In a recent paper Ju et al. [23] identified a putative
novel nuclear protein repressor of γ-globin gene tran-
scription, LYAR (human homologue of mouse Ly-1 anti-
body reactive clone). The LYAR DNA-binding motif
(GGTTAT) was identified by performing CASTing (cyc-
lic amplification and selection of targets) experiments
[23]. Results of EMSA (electrophoretic mobility shift
assay) and ChIP (chromatin immunoprecipitation) as-
says confirmed that LYAR binds a DNA region corre-
sponding to the 5′-untranslated region of the Aγ-globin
gene. Ju et al. formally demonstrated that LYAR is a
strong repressor of human fetal globin gene expression
in both K562 cells and primary human adult erythroid
progenitor cells. Interestingly, LYAR was found to dir-
ectly interact also with the methyltransferase PRMT5
which triggers the histone H4 Arg3 symmetric dimethy-
lation (H4R3me2s) mark. Altogether, these data indicate
that LYAR acts as a novel transcription factor that binds
the γ-globin gene, and is essential for silencing the γ-
globin gene [23].
The objective of this study was to investigate the pres-
ence of genetic variants in β-thalassemia patients poten-
tially affecting the LYAR binding site and the possible
association with the most common HbF-associated poly-
morphism, the XmnI polymorphism [18, 24, 25]. To this
aim we focused our attention on β-thalassemic patients
from the north-west Mediterranean area, in particular
those carrying the β039 and β+IVSI-110 thalassemia muta-
tions, allowing to compare β0- and β+-genotypes. The gen-
omic DNA from these patients was studied by full
sequencing of both the Gγ- and Aγ-globin genes.
Methods
Patients
A total of 75 β-thalassemia patients were recruited for
this study, including 31 β039/β039, 33 β039/β+IVSI-110,
9 β+IVSI-110/β+IVSI-110, one β0IVSI-1/β+IVSI-6 and
one β039/β+IVSI-6 patient. The β-thalassemia patients
have been recruited at Ferrara Hospital and Rovigo Hos-
pital. The Declaration of Helsinki was followed for the
collection of blood samples from β-thalassemia patients;
furthermore, specific approvals by the Ethical Commit-
tees of Ferrara Hospital and Rovigo Hospital were ob-
tained. All the β-thalassemia patients duly signed the
informed consent form before blood sampling.
Genomic DNA extraction, polymerase chain reaction (PCR)
and DNA sequencing
The genomic DNA from β-thalassemia patients was ex-
tracted from 500 μL of whole blood using the QIAamp®
DNA Blood Mini Kit (Qiagen, Hilden, Germany) as de-
scribed in Bianchi et al. [15]. PCR amplification of β-,
Aγ- or Gγ-globin genes and DNA sequencing methods
used in this study have been previously described by
Bianchi et al. [15]. The nucleotide sequences of the PCR
primers are reported in Table 1. BMR Genomics (Padua,
Italy) performed gene sequencing.
Erythroid progenitors (ErPCs) from β-thalassemia patients
The two-phase liquid culture procedure was employed
as previously described [26, 27]. The erythroid differenti-
ation status of ErPCs was verified analyzing transferrin
receptor (TrfR) and glycophorin A (GYPA) expression
by FACS (fluorescence-activated cell sorting) using the
BD FACScan™ system (Becton, Dickinson & Company,
Franklin Lakes, NJ, USA) and anti-human CD71 (TrfR)
FITC-conjugated antibody (Miltenyi Biotec GmbH, Ber-
gisch Gladbach, Germany) and anti-human CD235a
(GYPA) antibody PE-conjugated (Miltenyi Biotec
GmbH) as described elsewhere [28, 29]. Production of
hemoglobins was assessed by high performance liquid
chromatography (HPLC) as described elsewhere [11, 28].
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Statistical analysis
The results reported in this paper are usually presented
as average ± SD. The one-way ANOVA (ANalyses Of
VAriance between groups) software was used for com-
pare statistical differences between groups. The paired t
test of the GraphPad Prism Software was used to obtain
the p values. Differences were considered statistically
significant when p < 0.05 (*) and highly significant when
p < 0.01 (**) [28, 29].
Results
Presence of the rs368698783 (G->A) Aγ-globin gene poly-
morphism in β-thalassemia patients
In order to verify whether mutations affecting the
LYAR-binding site of the Aγ-globin gene are present
within our β-thalassemia patient population, sequencing
of the Aγ-globin genes was performed using genomic
DNA isolated from a total of 75 β-thalassemia patients,
including 31 β039/β039, 33 β039/β+IVSI-110, 9 β+IVSI-
110/β+IVSI-110, one β0IVSI-1/β+IVSI-6 and one β039/
β+IVSI-6 patient. Examples of the sequencing results
obtained are shown in Fig. 1a, which indicates that one
(G->A) rs368698783 polymorphism was found in pos-
ition +25 of the Aγ-globin gene, modifying the LYAR-
binding sequence from 5′-GGTTAT-3′ to 5′-GATTAT-
3′. For this reason, we called this mutation rs368698783
Aγ(+25 G->A) (see its location in Fig. 1b). In the exam-
ples reported in Fig. 1a, the representative homozygous
(G/G), heterozygous (G/A) and homozygous mutated
(A/A) genomic sequences are shown. In addition, as in-
dicated in the representative examples shown in Fig. 1a,
the G/G genotype is linked to the XmnI(−/−) haplotype;
in contrast the G/A and A/A Aγ(+25) genotypes are
linked to XmnI(−/+) and XmnI(+/+) haplotypes, respect-
ively. Figure 1b shows the location of the mutation
within the 5’UTR sequence of the Aγ-globin gene and
the nucleotide change concerning the 5′-GGTTAT-3′
LYAR binding site proposed by Ju et al. Notably, no
other nucleotide variations affecting the LYAR-binding
sequence were found in these 75 patients. Moreover, no
other mutations were found in the 607 bp and 613 bp
sequenced regions of the Aγ-globin and Gγ-globin
genes, respectively, with the exception of a 4 bp deletion
residing in the promoter region of the Aγ-globin gene
(HBG1: g.-225_-222delAGCA) [30], found in three
XmnI(−/−), Aγ(+25 G/G) β039/β+IVSI-110 patients. In
16/75 patients (21%) this Aγ(+25 G->A) polymorphism
was found in the heterozygous (G/A) state, while the
Aγ(+25) homozygous (A/A) state was found only in four
patients. While we cannot exclude the presence of other
mutations in the Aγ-globin genes of sub populations of β-
thalassemia patients, we can conclude that the Aγ(+25 G-
>A) concerning the rs368698783 polymorphism is the
most frequent mutation affecting this Aγ-globin gene re-
gion within our population, well representative of the
Mediterranean area.
The Aγ(+25 G->A) polymorphism is in complete linkage
disequilibrium with the XmnI polymorphism
Table 2 shows that in all the patients analyzed the
Aγ(+25 G->A) rs368698783 polymorphism is strictly
linked to the Gγ-XmnI polymorphism. In fact all the 55
Gγ-XmnI(−/−) patients were found to be Aγ(+25 G/G).
In addition, all the 16 Gγ-XmnI(−/+) patients were
found to be Aγ(+25 G/A) and the four Gγ-XmnI(+/+)
patients were found to be Aγ(+25 A/A). This very inter-
esting distribution allows to hypothesize that the XmnI
polymorphism, when present in this β-thalassemia pa-
tient population, is physically linked to the Aγ(+25 G-
>A) polymorphism.
Distribution of the Aγ(+25 G->A) polymorphism within
the β039/β039, β039/β+IVSI-110 and β+IVSI-110/β+IVSI-110
thalassemia patients
The results shown in Fig. 2 show that only one of the 9
β+IVSI-110/β+IVSI-110 patients was found to be Gγ-
XmnI(−/+) and Aγ(+25 G/A) (11.1%). The other patients
were Gγ-XmnI(−/−) and Aγ(+25 G/G) (88.9%). No pa-
tients exhibited a Gγ-XmnI(+/+) and Aγ(+25 A/A) com-
bination. By sharp contrast, in the β039/β+IVSI-110
cohort, the Gγ-XmnI(−/+) and Aγ(+25 G/A) patients
were found to be 6 (18.2%), 27 being Gγ-XmnI(−/−) and
Aγ(+25 G/G) (81.8%). Also in this case no patients ex-
hibited a Gγ-XmnI(+/+) and Aγ(+25 A/A) combination.
Finally, in the β039/β039 cohort the Gγ-XmnI(−/+) and
Aγ(+25 G/A) patients were found to be 7 (22.6%), 20 be-
ing Gγ-XmnI(−/−) and Aγ(+25 G/G) (64.5%). Unlike the
β+IVSI-110/β+IVSI-110 and the β039/β+IVSI-110 co-
horts, four β039/β039 patients exhibited a Gγ-XmnI(+/+)
and Aγ(+25 A/A) combination (12.9%). These data,
when analyzed together with the data shown in Table 2,





β-globin βF1 5′-GTG CCA GAA GAG CCA AGG ACA GG-3′
βR1 5′-AGT TCT CAG GAT CCA CGT GCA-3′
βF2 5′-GCC TGG CTC ACC TGG ACA-3′
βR2 5′-GTT GCC CAG GAG CTG TGG-3′
βF3 5′-ACA ATC CAG CTA CCA TTC TGC TTT-3′
βR3 5′-CAC TGA CCT CCC ACA TTC CCT TTT-3′
Aγ-globin AγF 5′-TTT CCT TAG AAA CCA CTG CTA ACT GAA A-3′
AγR 5′-TTG TGA TAG TAG CCT TGT CCT CCT CT-3′
Gγ-globin GγF 5′-TTC TTA TTT GGA AAC CAA TGC TTA CTA AAT-3′
GγR 5′-TTG TGA TAG TAG CCT TGT CCT CCT CT-3′
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support the hypothesis that the Gγ-XmnI and Aγ(+25 G-
>A) polymorphisms might be preferentially linked with
the β039 thalassemia mutation. To verify this hypothesis
the family trees of all the available families with β-
thalassemia patients carrying at least one β039-globin gene
were analyzed with respect to β-globin genes and Gγ-
XmnI and Aγ(+25 G->A) polymorphisms.
Association of the β039 thalassemia mutation with
Gγ-XmnI and Aγ(+25 G->A) polymorphisms
Figure 3a shows the family trees of a β039/β+IVSI-6, two
β039/β039 (out of three present in our cohort) and 5
β039/β+IVSI-110 patients (out of the 6 available). The re-
sults obtained firmly demonstrate that in the β039/
Fig. 1 Sequence analysis of selected Aγ- and Gγ-globin genes. a. Right: representative sequence analysis of the Aγ-globin gene surrounding the
region involved in LYAR binding site. The +25(G->A) polymorphism is arrowed. This corresponds to the already known rs368698783 polymorphism,
which was not analyzed in full detail in the β-thalassemia patient population (including patients carrying β+ and β0 mutations). In the examples
depicted the +25 Aγ-globin gene sequence is G/G (Fe6), G/A (Fe29) and A/A (Fe44). Left: the same genomic DNA has been sequenced at the XmnI
site, found to be −/− in Fe6, −/+ in Fe29 and +/+ in Fe44 samples. b. Location of the −158 XmnI Gγ-globin and +25 Aγ-globin gene sequences within
the Aγ- and Gγ-globin genes
Table 2 Distribution of the G->A Aγ-globin gene polymorphism
and association with the XmnI Gγ-globin gene polymorphism in
the β-thalassemia patients of this study
(G->A) mutation Aγ-globin gene XmnI polymorphism
Gγ-globin gene
G/G A/G A/A
55 0 0 −/−
0 16 0 +/−
0 0 4 +/+
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β+IVSI-6 family (Fe89) the Gγ-XmnI and Aγ(+25 G->A)
polymorphisms are linked to the β039 gene (Fig. 3a,
upper left side of the panel). In the two families with
β039/β039 patients (Fig. 3a, upper middle side of the
panel), one β039-globin gene (Fe29) and both β039-glo-
bin genes (Fe77) are associated with the Gγ-XmnI and
Aγ(+25 G->A) polymorphisms. More importantly, when
families with β039/β+IVSI-110 were considered, one
(Fe11) was not informative (the genome of the mother
was not available), while in patients Fe31, Fe34, Fe88
and Fe91 the β039 genotype was structurally linked to
the Gγ-XmnI and Aγ(+25 G->A) polymorphisms
combination. These polymorphisms were not associ-
ated with the β+IVSI-110 gene, as summarized in Fig.
Fig. 2 Distribution of the −158 XmnI Gγ-globin and +25 Aγ-globin gene polymorphisms within the studied β-thalassemia patients. The studied
73 patients were divided in β039/β039, β039/β+IVSI-110 and β+IVSI-110/β+IVSI-110 subgroups and the −158 XmnI Gγ-globin and +25 Aγ-globin
gene polymorphisms determined by direct sequencing
Fig. 3 Genetic trees of the informative β-thalassemia families studied. a The analysis of the transmission of the −158 XmnI Gγ-globin and
+25 Aγ-globin gene sequences from the parents to the studied β-thalassemia patients allowed to determine the linkage to the β039
mutation. b, c Most frequent XmnI Gγ-globin and +25 Aγ-globin genes linked to β039 (b) and β+IVSI-110 (c) globin genes. The comparative analysis
does not include Fe11 because not informative. N.A. = not available
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3b. These data clearly indicate that in the population
analyzed the Gγ-XmnI and Aγ(+25 G->A) polymor-
phisms cosegregate with the β039-globin gene muta-
tion in the majority of the families of compound-
heterozygous β0-thalassemia patients.
Production of fetal hemoglobin by erythroid precursor
cells (ErPCs) from β039/β039 thalassemia patients:
Relationship with Gγ-XmnI and Aγ(+25 G->A)
polymorphisms
In order to verify possible relationships between the Gγ-
XmnI and Aγ(+25 G->A) polymorphisms configuration,
30 available β039/β039 patients were recruited, periph-
eral blood isolated, erythroid precursor cells (ErPCs) se-
lected and erythropoietin (EPO)-induced as elsewhere
reported [27, 28]. After 7 days of EPO treatment, the
erythroid differentiation was confirmed by benzidine-
staining (looking at hemoglobin production) and FACS
analysis of transferrin receptor and glycophorin A ex-
pression, as reported elsewhere [28] (data not shown).
After demonstration that more than 80% of the cells
were benzidine, TrfR and GYPA positive, HPLC analysis
was performed to quantify fetal hemoglobin (HbF) pro-
duction. Figure 4 (panels a and b) shows the representa-
tive HPLC profile of two ErPC lysates (arrowed in Fig.
4c), displaying a low (Fig. 4a) and high (Fig. 4b) HbF
relative production. All the data obtained are shown in
Fig. 4c, in which the ErPCs are stratified with respect to
the Gγ-XmnI and Aγ(+25 G->A) polymorphisms
configuration. As clearly evident, a significant correl-
ation can be observed between the Gγ-XmnI and
Aγ(+25 G->A) polymorphisms configuration and ele-
vated production of HbF. In fact the average HbF pro-
duction by ErPCs from β039/β039, Gγ-XmnI(+/+) and
Aγ(+25 A/A) patients was 66.1 ± 14.1%, a value signifi-
cantly higher than those found in ErPCs from Gγ-
XmnI(−/−) and Aγ(+25 G/G) or Gγ-XmnI(−/+) and
Aγ(+25 G/A) patients. This finding suggests that Gγ-
XmnI and Aγ(+25 G->A) polymorphisms should be
present in both alleles for maximal potentiation of HbF
production, even if not “per se” sufficient and probably
acting with other “HbF modifiers”, since all the Gγ-
XmnI(+/+) and Aγ(+25 A/A) patients did not carry any
detectable alteration of the α-globin gene asset. In any
case, the cellular system here described might help to
dissect genetic control of fetal-hemoglobin persistence
and disease phenotypes, especially considering the possi-
bility to access cellular biobanks from β-thalassemia pa-
tients stratified with respect to genotype, Gγ-XmnI and
Aγ(+25) polymorphisms, enabling cryopreservation and
usage of the cryopreserved and thawed cells for molecu-
lar biology studies [31].
Discussion
Clinical observations have shown that increased levels of
fetal hemoglobin (HbF) can ameliorate the severity of
the disorders of β-hemoglobin, including β-thalassemia
[7]. High HbF levels are associated with transcriptional
Fig. 4 Relationship between the −158 XmnI Gγ-globin and +25 Aγ-globin gene polymorphisms and the level of fetal hemoglobin (HbF) in erythroid
precursor cells from β039/β039 thalassemia patients. a, b. Representative HPLC analyses of the cytoplasms isolated from two ErPCs populations, one
exhibiting low levels of HbF (a) and the other exhibiting high HbF levels (b) (arrowed in panel c). c HbF levels in ErPCs from 30 β039/β039 thalassemia
patients (stratified on the basis of the 158 XmnI Gγ-globin and +25 Aγ-globin gene polymorphisms)
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effects on the γ-globin genes, which are associated with
the biological activity of several transcription repressors,
including MYB, BCL11A, Oct-1, KLF1 and others [16–
19, 31–33]. A recent paper has pointed out the attention
on a new putative repressor of the γ-globin gene, LYAR
(human homologue of mouse Ly-1 antibody reactive
clone), recognizing the Aγ-globin gene sequence 5′-
GGTTAT-3′. Interestingly, several alterations within this
consensus sequence for LYAR are associated with a de-
crease binding efficiency [23].
At present, no extensive analysis of this sequence has
been reported in β-thalassemia patients; no attempts
have been made to verify a possible association with the
major HbF associated polymorphism, the Gγ-globin-
XmnI; finally, no extensive analysis has been reported on
possible linkage with β0- and β+-globin gene mutations.
In this paper we report the sequencing of the Aγ-
globin genes performed on genomic DNA isolated from
a total of 75 β-thalassemia patients, including 31 β039/
β039, 33 β039/β+IVSI-110, 9 β+IVSI-110/β+IVSI-110, one
β0IVSI-1/β+IVSI-6 and one β039/β+IVSI-6.
The major results of this paper are the following: (a) a
G->A mutation at the level of the rs368698783 poly-
morphism is present in β-thalassemia patients in the
5’UTR sequence (+25) of the Aγ-globin gene, affecting
the LYAR binding site 5′-GGTTAT-3′ sequence (Fig. 1);
(b) no other mutations of the LYAR binding site were
found; (c) this Aγ(+25 G->A) polymorphism is in
complete linkage disequilibrium with a promoter variant
of the Gγ-globin-gene (the XmnI polymorphism,
rs7482144, C->T); (d) the Aγ(+25 G->A) and Gγ-globin-
XmnI polymorphisms are linked with the β039-globin
gene, but not with the β+IVSI-110-globin gene (Figs. 2
and 3). Further genetic analysis in different β-
thalassemia patient population is necessary (a) to extend
this specific finding to other β0-thalassemia mutations
and (b) to verify the link of Aγ(+25 G->A) and Gγ-
globin-XmnI (C->T) polymorphisms with the β039-glo-
bin gene in a statistically more significant number of
patients.
Conclusions
It is interesting to note that the Aγ(+25 G->A) rs368698783
polymorphism is expected to deeply alter the LYAR binding
activity, thereby activating the Aγ-globin gene [23]. One
possibility, which deserves to be verified in further studies, is
that rs368698783, rather than the XmnI polymorphism,
could be the physiologically (and even clinically) active vari-
ant in hemoglobinopathy patients carrying haplotypes in-
cluding the XmnI(+) allele.
In respect to this point, our last conclusion is that the
Aγ(+25 G->A) and Gγ-globin-XmnI polymorphisms
might be associated with high HbF in erythroid precursor
cells isolated from the β039/β039 thalassemia patients
(Fig. 4), in agreement with several studies suggesting the
association between XmnI polymorphism and high HbF
production [18, 24, 34, 35].
On the other hand, as a potential explanation of our
findings, we hypothesize that in β-thalassemia the Gγ-
globin-XmnI/Aγ-globin-(G->A) genotype is frequently
under genetic linkage with β0-thalassemia mutations,
but not with the β+-thalassemia mutation here studied
(i.e. β+IVSI-110). One hypothesis is the very interesting
possibility that this genetic combination has been se-
lected within the population of the β0-thalassemia pa-
tients, due to its functional association with high HbF.
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